VaxInnate is developing vaccines to respond to urgent public health needs. The company's technology is broadly applicable for providing protection against and treatment for a wide range of diseases, including bacterial, viral, and parasitic infections. Current product development focuses on one of the most vexing and costly public health challenges - influenza.

Influenza is one of the most communicable diseases. The flu typically affects children and the elderly the hardest. Complications from flu cause more than 200,000 hospitalizations in the U.S. annually, and lead to approximately 36,000 deaths each year.

Novel influenza strains are widely generated in populations of domestic and wild fowl, pigs, humans and other animals. Most strains only infect animals. Of those that spread to humans, many are easily combated by a healthy person's immune system. Occasionally, however, an entirely new strain emerges that spreads from animals to humans. Because humans lack any previous exposure to and thus protection from these novel viruses, these strains may cause a pandemic involving widespread, sometimes severe disease.

 

Flagellin.HuHA and flagellin.AvHA : recombinant fusion proteins linking a potent immune stimulator, the bacterial protein flagellin, with the most immunoprotective domain of viral hemagglutinin (HA) - the globular head - derived from human and avian influenza virus, respectively. Clinical trial evaluations of our vaccines against two different HA strains, including the 2009 H1N1 pandemic strain, in more than 400 subjects have demonstrated that they are well tolerated and highly effective, eliciting strong virus neutralizing antibody responses at low microgram doses. Importantly, these vaccines proved potent even in elderly subjects, a population that is most at risk for flu and responds poorly to currently approved flu vaccines.

Another significant advantage of VaxInnate’s technology is that our vaccines are manufactured using bacterial expression/fermentation for the first time in flu vaccine manufacturing. Bacterial expression is highly efficient with near unlimited capacity and the final products are pure and well characterized biopharmaceutical proteins, unlike most other flu vaccines. The efficiency of this manufacturing process can provide rapid and cost effective production of seasonal and pandemic vaccines, providing the first to last dose requirements for the North American, European and even global needs in only a few months after flu strain identification, even in the case of flu pandemics, a speed and capacity unmatched by any other technology.